Mural Oncology was spun out of Alkermes plc last year to continue development of the IL-2 cytokine nemvaleukin, a promising immuno-oncology asset with a notably challenging mechanism. The company is establishing business operations, fine-tuning clinical trials and working on the next assets it plans to move into the clinic as it awaits key data readouts on nemvaleukin.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?